Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 118

1.

Quantitative transcranial sonography of the substantia nigra as a predictor of therapeutic response to intravenous iron therapy in restless legs syndrome.

Garcia-Malo C, Wanner V, Miranda C, Romero Peralta S, Agudelo L, Cano-Pumarega I, Granizo JJ, Garcia-Borreguero D.

Sleep Med. 2020 Feb;66:123-129. doi: 10.1016/j.sleep.2019.09.020. Epub 2019 Oct 30.

PMID:
31875533
2.

Treating restless legs syndrome in the context of sleep disordered breathing comorbidity.

Romero-Peralta S, Cano-Pumarega I, Garcia-Malo C, Agudelo Ramos L, García-Borreguero D.

Eur Respir Rev. 2019 Oct 1;28(153). pii: 190061. doi: 10.1183/16000617.0061-2019. Print 2019 Sep 30. Review.

4.

Adenosine mechanisms and hypersensitive corticostriatal terminals in restless legs syndrome. Rationale for the use of inhibitors of adenosine transport.

Ferré S, Quiroz C, Rea W, Guitart X, García-Borreguero D.

Adv Pharmacol. 2019;84:3-19. doi: 10.1016/bs.apha.2018.12.005. Epub 2019 Jan 18.

PMID:
31229176
5.

Non-dopaminergic vs. dopaminergic treatment options in restless legs syndrome.

Wanner V, Garcia Malo C, Romero S, Cano-Pumarega I, García-Borreguero D.

Adv Pharmacol. 2019;84:187-205. doi: 10.1016/bs.apha.2019.02.003. Epub 2019 Mar 14. Review.

PMID:
31229171
6.

Reduced response to gabapentin enacarbil in restless legs syndrome following long-term dopaminergic treatment.

Garcia-Borreguero D, Cano-Pumarega I, Garcia Malo C, Cruz Velarde JA, Granizo JJ, Wanner V.

Sleep Med. 2019 Mar;55:74-80. doi: 10.1016/j.sleep.2018.11.025. Epub 2018 Dec 26.

7.

Withdrawal symptoms following dopaminergic treatment of RLS.

Garcia-Borreguero D.

Sleep Med. 2019 Jul;59:117-118. doi: 10.1016/j.sleep.2018.10.001. Epub 2018 Oct 10. No abstract available.

PMID:
30555027
8.

New Insights into the Neurobiology of Restless Legs Syndrome.

Ferré S, García-Borreguero D, Allen RP, Earley CJ.

Neuroscientist. 2019 Apr;25(2):113-125. doi: 10.1177/1073858418791763. Epub 2018 Jul 26. Review.

PMID:
30047288
9.

Treatment of restless legs syndrome/Willis-Ekbom disease with the non-selective ENT1/ENT2 inhibitor dipyridamole: testing the adenosine hypothesis.

Garcia-Borreguero D, Guitart X, Garcia Malo C, Cano-Pumarega I, Granizo JJ, Ferré S.

Sleep Med. 2018 May;45:94-97. doi: 10.1016/j.sleep.2018.02.002. Epub 2018 Feb 24.

PMID:
29680437
10.

Management of treatment failure in restless legs syndrome (Willis-Ekbom disease).

Garcia-Borreguero D, Cano-Pumarega I, Marulanda R.

Sleep Med Rev. 2018 Oct;41:50-60. doi: 10.1016/j.smrv.2018.01.001. Epub 2018 Jan 9. Review.

PMID:
29602660
11.

Evidence-based and consensus clinical practice guidelines for the iron treatment of restless legs syndrome/Willis-Ekbom disease in adults and children: an IRLSSG task force report.

Allen RP, Picchietti DL, Auerbach M, Cho YW, Connor JR, Earley CJ, Garcia-Borreguero D, Kotagal S, Manconi M, Ondo W, Ulfberg J, Winkelman JW; International Restless Legs Syndrome Study Group (IRLSSG).

Sleep Med. 2018 Jan;41:27-44. doi: 10.1016/j.sleep.2017.11.1126. Epub 2017 Nov 24.

12.

Pivotal Role of Adenosine Neurotransmission in Restless Legs Syndrome.

Ferré S, Quiroz C, Guitart X, Rea W, Seyedian A, Moreno E, Casadó-Anguera V, Díaz-Ríos M, Casadó V, Clemens S, Allen RP, Earley CJ, García-Borreguero D.

Front Neurosci. 2018 Jan 8;11:722. doi: 10.3389/fnins.2017.00722. eCollection 2017.

13.

European guideline for the diagnosis and treatment of insomnia.

Riemann D, Baglioni C, Bassetti C, Bjorvatn B, Dolenc Groselj L, Ellis JG, Espie CA, Garcia-Borreguero D, Gjerstad M, Gonçalves M, Hertenstein E, Jansson-Fröjmark M, Jennum PJ, Leger D, Nissen C, Parrino L, Paunio T, Pevernagie D, Verbraecken J, Weeß HG, Wichniak A, Zavalko I, Arnardottir ES, Deleanu OC, Strazisar B, Zoetmulder M, Spiegelhalder K.

J Sleep Res. 2017 Dec;26(6):675-700. doi: 10.1111/jsr.12594. Epub 2017 Sep 5.

14.

Treatment of restless legs syndrome with the selective AMPA receptor antagonist perampanel.

Garcia-Borreguero D, Cano I, Granizo JJ.

Sleep Med. 2017 Jun;34:105-108. doi: 10.1016/j.sleep.2017.03.012. Epub 2017 Mar 30.

PMID:
28522077
15.

New concepts in the management of restless legs syndrome.

Garcia-Borreguero D, Cano-Pumarega I.

BMJ. 2017 Feb 27;356:j104. doi: 10.1136/bmj.j104. Review.

PMID:
28242627
16.

Restless legs syndrome (Willis-Ekbom disease): an urgent need for better treatments.

Garcia-Borreguero D.

Sleep Med. 2017 Feb;30:266-267. doi: 10.1016/j.sleep.2015.12.009. Epub 2016 Jan 4. No abstract available.

PMID:
28041721
17.

In search of alternatives to dopaminergic ligands for the treatment of restless legs syndrome: iron, glutamate, and adenosine.

Ferré S, Earley C, Gulyani S, Garcia-Borreguero D.

Sleep Med. 2017 Mar;31:86-92. doi: 10.1016/j.sleep.2016.08.019. Epub 2016 Nov 1. Review.

PMID:
27899234
18.

Introduction: Towards a better understanding of the science of RLS/WED.

Garcia Borreguero D, Winkelmann J, Allen RP.

Sleep Med. 2017 Mar;31:1-2. doi: 10.1016/j.sleep.2016.10.007. Epub 2016 Oct 28. No abstract available.

PMID:
27894926
19.

World Association of Sleep Medicine (WASM) 2016 standards for recording and scoring leg movements in polysomnograms developed by a joint task force from the International and the European Restless Legs Syndrome Study Groups (IRLSSG and EURLSSG).

Ferri R, Fulda S, Allen RP, Zucconi M, Bruni O, Chokroverty S, Ferini-Strambi L, Frauscher B, Garcia-Borreguero D, Hirshkowitz M, Högl B, Inoue Y, Jahangir A, Manconi M, Marcus CL, Picchietti DL, Plazzi G, Winkelman JW, Zak RS; International and European Restless Legs Syndrome Study Groups (IRLSSG and EURLSSG).

Sleep Med. 2016 Oct;26:86-95. doi: 10.1016/j.sleep.2016.10.010. Epub 2016 Nov 7.

PMID:
27890390
20.

Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation.

Garcia-Borreguero D, Silber MH, Winkelman JW, Högl B, Bainbridge J, Buchfuhrer M, Hadjigeorgiou G, Inoue Y, Manconi M, Oertel W, Ondo W, Winkelmann J, Allen RP.

Sleep Med. 2016 May;21:1-11. doi: 10.1016/j.sleep.2016.01.017. Epub 2016 Feb 23.

21.

Efficacy of gabapentin enacarbil in adult patients with severe primary restless legs syndrome.

Lee DO, Buchfuhrer MJ, Garcia-Borreguero D, Avidan AY, Ahmed M, Hays R, Ondo WG, Jaros MJ, Kim R, Shang G.

Sleep Med. 2016 Mar;19:50-6. doi: 10.1016/j.sleep.2015.11.002. Epub 2015 Nov 14.

PMID:
27198947
22.

Effects of rotigotine on daytime symptoms in patients with primary restless legs syndrome: a randomized, placebo-controlled study.

Garcia-Borreguero D, Allen R, Hudson J, Dohin E, Grieger F, Moran K, Schollmayer E, Smit R, Winkelman J.

Curr Med Res Opin. 2016;32(1):77-85. doi: 10.1185/03007995.2015.1103216. Epub 2015 Nov 16.

PMID:
26569149
23.

Dopaminergic Augmentation in Restless Legs Syndrome/Willis-Ekbom Disease: Identification and Management.

García-Borreguero D.

Sleep Med Clin. 2015 Sep;10(3):287-92, xiii. doi: 10.1016/j.jsmc.2015.05.020. Epub 2015 Jul 17. Review.

PMID:
26329438
24.

Augmentation of restless leg syndrome (Willis-Ekbom disease) during long-term dopaminergic treatment.

Garcia-Borreguero D, Benitez A, Kohnen R, Allen R.

Postgrad Med. 2015;127(7):716-25. doi: 10.1080/00325481.2015.1058140. Epub 2015 Jun 16. Review.

PMID:
26077324
25.

Review of quality of life instruments for the restless legs syndrome/Willis-Ekbom Disease (RLS/WED): critique and recommendations.

Walters AS, Frauscher B, Allen R, Benes H, Chaudhuri KR, Garcia-Borreguero D, Lee HB, Picchietti DL, Trenkwalder C, Martinez-Martin P, Stebbins GT, Schrag A; MDS Committee on Rating Scales.

J Clin Sleep Med. 2014 Dec 15;10(12):1351-7. doi: 10.5664/jcsm.4300. Review.

26.

Review of diagnostic instruments for the restless legs syndrome/Willis-Ekbom Disease (RLS/WED): critique and recommendations.

Walters AS, Frauscher B, Allen R, Benes H, Chaudhuri KR, Garcia-Borreguero D, Lee HB, Picchietti DL, Trenkwalder C, Martinez-Martin P, Stebbins GT, Schrag A; MDS Committee on Rating Scales.

J Clin Sleep Med. 2014 Dec 15;10(12):1343-9. doi: 10.5664/jcsm.4298. Review.

27.

Review of Severity Rating Scales for Restless Legs Syndrome: Critique and Recommendations.

Walters AS, Frauscher B, Allen R, Benes H, Chaudhuri KR, Garcia-Borreguero D, Lee HB, Picchietti DL, Trenkwalder C, Martinez-Martin P, Schrag A, Stebbins G.

Mov Disord Clin Pract. 2014 Sep 30;1(4):317-324. doi: 10.1002/mdc3.12088. eCollection 2014 Dec. Review.

28.

Altered brain iron homeostasis and dopaminergic function in Restless Legs Syndrome (Willis-Ekbom Disease).

Earley CJ, Connor J, Garcia-Borreguero D, Jenner P, Winkelman J, Zee PC, Allen R.

Sleep Med. 2014 Nov;15(11):1288-301. doi: 10.1016/j.sleep.2014.05.009. Epub 2014 Jun 16. Review.

PMID:
25201131
29.

Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria--history, rationale, description, and significance.

Allen RP, Picchietti DL, Garcia-Borreguero D, Ondo WG, Walters AS, Winkelman JW, Zucconi M, Ferri R, Trenkwalder C, Lee HB; International Restless Legs Syndrome Study Group.

Sleep Med. 2014 Aug;15(8):860-73. doi: 10.1016/j.sleep.2014.03.025. Epub 2014 May 17.

PMID:
25023924
30.

An update on restless legs syndrome (Willis-Ekbom disease): clinical features, pathogenesis and treatment.

Garcia-Borreguero D, Williams AM.

Curr Opin Neurol. 2014 Aug;27(4):493-501. doi: 10.1097/WCO.0000000000000117. Review.

PMID:
24978636
31.

Pregabalin versus pramipexole: effects on sleep disturbance in restless legs syndrome.

Garcia-Borreguero D, Patrick J, DuBrava S, Becker PM, Lankford A, Chen C, Miceli J, Knapp L, Allen RP.

Sleep. 2014 Apr 1;37(4):635-43. doi: 10.5665/sleep.3558.

32.

Comparison of pregabalin with pramipexole for restless legs syndrome.

Allen RP, Chen C, Garcia-Borreguero D, Polo O, DuBrava S, Miceli J, Knapp L, Winkelman JW.

N Engl J Med. 2014 Feb 13;370(7):621-31. doi: 10.1056/NEJMoa1303646.

33.

Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension.

Trenkwalder C, Beneš H, Grote L, García-Borreguero D, Högl B, Hopp M, Bosse B, Oksche A, Reimer K, Winkelmann J, Allen RP, Kohnen R; RELOXYN Study Group.

Lancet Neurol. 2013 Dec;12(12):1141-50. doi: 10.1016/S1474-4422(13)70239-4. Epub 2013 Oct 18. Erratum in: Lancet Neurol. 2013 Dec;12(12):1133.

PMID:
24140442
34.

A review of the effects of pregabalin on sleep disturbance across multiple clinical conditions.

Roth T, Arnold LM, Garcia-Borreguero D, Resnick M, Clair AG.

Sleep Med Rev. 2014 Jun;18(3):261-71. doi: 10.1016/j.smrv.2013.07.005. Epub 2013 Oct 9. Review.

PMID:
24119681
35.

Catalogue of knowledge and skills for sleep medicine.

Penzel T, Pevernagie D, Dogas Z, Grote L, de Lacy S, Rodenbeck A, Bassetti C, Berg S, Cirignotta F, d'Ortho MP, Garcia-Borreguero D, Levy P, Nobili L, Paiva T, Peigneux P, Pollmächer T, Riemann D, Skene DJ, Zucconi M, Espie C; Sleep Medicine Committee; European Sleep Research Society.

J Sleep Res. 2014 Apr;23(2):222-38. doi: 10.1111/jsr.12095. Epub 2013 Oct 7.

36.

Willis-Ekbom Disease Foundation revised consensus statement on the management of restless legs syndrome.

Silber MH, Becker PM, Earley C, Garcia-Borreguero D, Ondo WG; Medical Advisory Board of the Willis-Ekbom Disease Foundation.

Mayo Clin Proc. 2013 Sep;88(9):977-86. doi: 10.1016/j.mayocp.2013.06.016.

PMID:
24001490
37.

The long-term treatment of restless legs syndrome/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group.

Garcia-Borreguero D, Kohnen R, Silber MH, Winkelman JW, Earley CJ, Högl B, Manconi M, Montplaisir J, Inoue Y, Allen RP.

Sleep Med. 2013 Jul;14(7):675-84. doi: 10.1016/j.sleep.2013.05.016.

38.

Validation of the Multiple Suggested Immobilization Test: A Test for the Assessment of Severity of Restless Legs Syndrome (Willis-Ekbom Disease).

Garcia-Borreguero D, Kohnen R, Boothby L, Tzonova D, Larrosa O, Dunkl E.

Sleep. 2013 Jul 1;36(7):1101-1109.

39.

Safety and efficacy of rotigotine transdermal patch in patients with restless legs syndrome: a post-hoc analysis of patients taking 1 - 3 mg/24 h for up to 5 years.

Dohin E, Högl B, Ferini-Strambi L, Schollmayer E, Fichtner A, Bauer L, García-Borreguero D.

Expert Opin Pharmacother. 2013 Jan;14(1):15-25. doi: 10.1517/14656566.2013.758251. Epub 2012 Dec 21.

PMID:
23256574
40.

Efficacy, safety and risk of augmentation of rotigotine for treating restless legs syndrome.

Inoue Y, Hirata K, Hayashida K, Hattori N, Tomida T, Garcia-Borreguero D; Rotigotine Study Group.

Prog Neuropsychopharmacol Biol Psychiatry. 2013 Jan 10;40:326-33. doi: 10.1016/j.pnpbp.2012.10.012. Epub 2012 Oct 25.

PMID:
23103551
41.

European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society.

Garcia-Borreguero D, Ferini-Strambi L, Kohnen R, O'Keeffe S, Trenkwalder C, Högl B, Benes H, Jennum P, Partinen M, Fer D, Montagna P, Bassetti CL, Iranzo A, Sonka K, Williams AM; European Federation of Neurological Societies; European Neurological Society; European Sleep Research Society.

Eur J Neurol. 2012 Nov;19(11):1385-96. doi: 10.1111/j.1468-1331.2012.03853.x. Epub 2012 Sep 3.

PMID:
22937989
42.

From restless legs syndrome to Willis-Ekbom disease: a condition reaches full age.

García-Borreguero D.

Sleep Med Rev. 2012 Aug;16(4):281-2. doi: 10.1016/j.smrv.2012.03.004. Epub 2012 Apr 22. No abstract available.

PMID:
22531480
43.

Augmentation in the treatment of restless legs syndrome with transdermal rotigotine.

Beneš H, García-Borreguero D, Ferini-Strambi L, Schollmayer E, Fichtner A, Kohnen R.

Sleep Med. 2012 Jun;13(6):589-97. doi: 10.1016/j.sleep.2011.09.016. Epub 2012 Apr 13.

PMID:
22503658
44.

Systematic evaluation of augmentation during treatment with ropinirole in restless legs syndrome (Willis-Ekbom disease): results from a prospective, multicenter study over 66 weeks.

García-Borreguero D, Högl B, Ferini-Strambi L, Winkelman J, Hill-Zabala C, Asgharian A, Allen R.

Mov Disord. 2012 Feb;27(2):277-83. doi: 10.1002/mds.24889. Epub 2012 Jan 4.

PMID:
22328464
45.

Breakthrough symptoms during the daytime in patients with restless legs syndrome (Willis-Ekbom disease).

Tzonova D, Larrosa O, Calvo E, Granizo JJ, Williams AM, de la Llave Y, García-Borreguero D.

Sleep Med. 2012 Feb;13(2):151-5. doi: 10.1016/j.sleep.2011.09.015. Epub 2012 Jan 26.

PMID:
22281003
46.

Treatment of restless legs syndrome with rotigotine.

García-Borreguero D, Oertel W, Trenkwalder C; SP710 study group.

Lancet Neurol. 2011 Oct;10(10):872-3. doi: 10.1016/S1474-4422(11)70218-6. No abstract available.

PMID:
21939896
47.

Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study.

Oertel W, Trenkwalder C, Beneš H, Ferini-Strambi L, Högl B, Poewe W, Stiasny-Kolster K, Fichtner A, Schollmayer E, Kohnen R, García-Borreguero D; SP710 study group.

Lancet Neurol. 2011 Aug;10(8):710-20. doi: 10.1016/S1474-4422(11)70127-2. Epub 2011 Jun 24.

PMID:
21705273
48.

High pain frequency in narcolepsy with cataplexy.

Dauvilliers Y, Bayard S, Shneerson JM, Plazzi G, Myers AJ, Garcia-Borreguero D.

Sleep Med. 2011 Jun;12(6):572-7. doi: 10.1016/j.sleep.2011.01.010. Epub 2011 May 12.

PMID:
21570344
49.

[Consensus document on sleep apnea-hypopnea in children. Prologue].

Terán-Santos J, García Borreguero D.

Arch Bronconeumol. 2011 May;47 Suppl 5:1. Spanish. No abstract available.

PMID:
22866332
50.

Dopaminergic augmentation of restless legs syndrome: the scope of the problem.

García-Borreguero D, Williams AM.

Sleep Med. 2011 May;12(5):425-6. doi: 10.1016/j.sleep.2011.03.004. Epub 2011 Apr 13. No abstract available.

PMID:
21493133

Supplemental Content

Loading ...
Support Center